- Recent insider selling by multiple executives, including the CEO, suggests a notable trend in Cytokinetics stock activity.
- CEO Robert I. Blum executed significant share sales, including a large block under a pre-arranged Rule 10b5-1 trading plan, totaling millions of dollars.
- Despite its 50-day moving average being above its 200-day moving average, Cytokinetics currently trades below both, and its negative P/E ratio indicates unprofitability over the last twelve months.
Cytokinetics, Incorporated (NASDAQ: CYTK) is a late-stage biopharmaceutical company. It focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company has a market capitalization of approximately $8.07 billion and its stock has a 52-week range between $29.31 and $88.31.
A recent theme for the company is insider stock sales. On September 28, 2026, President and CEO Blum Robert I sold 7,500 shares of Cytokinetics. The transaction was completed at a price of $65.46 per share, for a total value of around $490,950.00. After this sale, Blum's ownership in the company stands at 278,544 shares.
This sale is part of a larger pattern of selling by the CEO. On September 15th, Blum sold a much larger block of 97,926 shares at an average price of $69.33 each. This earlier transaction totaled approximately $6.79 million and was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows insiders to set up a trading schedule in advance.
Other company leaders are also selling stock. Executive Vice President Fady Malik sold 3,500 shares on September 22nd at an average price of $68.29. As highlighted by Defense World, Malik also sold 3,500 shares on September 8th for $75.46 each and another 3,500 shares on August 18th for $75.82 each.
From a market perspective, Cytokinetics has a negative price-to-earnings (P/E) ratio of -9.61. A negative P/E ratio means the company has not been profitable over the last twelve months. The stock's 50-day moving average of $77.15 is above its 200-day moving average of $72.85, but the current price is below both averages.
